ABSTRACT
This chapter describes the improved efficacy of nanoparticulate drug delivery systems as compared with microsized drug delivery systems, current fabrication methods, and the prospective possibility of developing commercial products that can benefit patients. Introducing nanotechnology into the drug carrier architecture makes it more attractive in many different fields based on its advantageous properties as compared with other conventional systems. In drug delivery, however, nanotechnology also refers to drug delivery vehicles in micron size, simply because many drug delivery systems are produced in micron size ranges. The advantages of niosomes over liposomes are increased stability, low cost of production, and no need to handle variable purity of phospholipids. To overcome this phenomenon, niosome and liposome systems were introduced to incorporate the acyclovir, and drug release profiles were compared. Clathrin-independent endocytosis Clathrin-dependent endocytosis Recycling endosome Golgi Lysosome Lecithin Nonionic surfactant Lipid nanocapsules have several beneficial properties for making them a good drug delivery vehicle for increased bioavailability.
